O'connor, O, Özcan, M, Jacobsen, E, Roncero Vidal, JM, Trotman, J, Demeter, J, Masszi, T, Pereira, J, Ramchandren, R, Beaven, A, Caballero Barringon, D, Horwitz, S, Lennard, A, Turgut, M, Hamerschlak, N, d'Amore, F A, Foss, F, Kim, WS, Leonard, JP, Zinzani, PL, Chiattone, CS, His, ED, Liu, H, Sheldon-Waniga, E, Dansky Ullmann, C, Leonard, EJ & Shustov, A 2017, ' Randomised phase III study of alisertib or investigator's choice (selected singe agent) in patients with relapsed or refractory peripheral T-cell lymphoma. ', Lancet Oncology .